Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inactivation of cofilin-1 in Mcpt5-Cre-nf-Cfl1<sup>fl/fl</sup> mice prevents the formation of connective tissue mast cells without affecting basophils: a new tool to investigate the specific role of CTMCs in disease.

Frontiers in immunology·2026
Same author

CD73 Expression by CD4 <sup>+</sup> T Cells Marks Early Effector Memory T Cells.

Immunology·2025
Same author

IL-17A-producing CD8<sup>+</sup> T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts.

Gut·2023
Same author

IL-17 Signaling in Keratinocytes Orchestrates the Defense against Staphylococcus aureus Skin Infection.

The Journal of investigative dermatology·2023
Same author

Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone.

Proceedings of the National Academy of Sciences of the United States of America·2021
Same author

Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity.

The Journal of investigative dermatology·2021
Same journal

A zinc deficiency leads to non-inflammatory pruritus by modifying opioid receptor signaling.

Journal of dermatological science·2026
Same journal

Collagen XVIIα1 in skin and hair aging: Mechanisms, stem cell niche regulation, and translational strategies.

Journal of dermatological science·2026
Same journal

A shift towards a type I immune response in chronic atopic dermatitis favours an IL-15 dependent tissue resident memory cell niche.

Journal of dermatological science·2026
Same journal

Psychological stress exacerbates vitiligo via dysregulated proteolysis of substance P and MRGPRX2-dependent mast cell activation.

Journal of dermatological science·2026
Same journal

KRT10-nEDD-superficial: A novel phenotype characterized by vesicles and skin peeling.

Journal of dermatological science·2026
Same journal

Synergistic enhancement of PD-L1 expression from DNA repair dysfunction and UV exposure in xeroderma pigmentosum: Potential therapeutic role of PD-L1 inhibitors.

Journal of dermatological science·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Isolation and Th17 Differentiation of Na&#239;ve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.6K

IL-17 for therapy.

Florian C Kurschus1, Sonja Moos1

  • 1Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.

Journal of Dermatological Science
|June 22, 2017
PubMed
Summary
This summary is machine-generated.

Interleukin-17 (IL-17) is a key driver of psoriasis. Overexpressing IL-17 in mice caused severe skin inflammation, mimicking human psoriasis and its comorbidities, validating IL-17 as a therapeutic target.

Keywords:
AutoimmunityIL-17IL-17 neutralizing monoclonal antibodiesIL-17 receptorPsoriasis

More Related Videos

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

4.5K
Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

1.0K

Related Experiment Videos

Last Updated: Feb 28, 2026

Isolation and Th17 Differentiation of Na&#239;ve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.6K
Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

4.5K
Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

1.0K

Area of Science:

  • Immunology
  • Dermatology
  • Molecular Biology

Background:

  • Interleukin-17 (IL-17) is a critical cytokine implicated in inflammatory diseases.
  • Therapeutic monoclonal antibodies targeting IL-17, such as Secukinumab, Ixekizumab, and Brodalumab, are approved for treating psoriasis and related conditions.
  • Understanding the precise role of IL-17 in pathogenesis is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of IL-17A in the development of skin inflammation.
  • To establish a mouse model that spontaneously develops psoriasis-like dermatitis.
  • To explore the utility of this model for studying IL-17-mediated pathology and comorbidities.

Main Methods:

  • Generation of transgenic mice with keratinocyte-specific overexpression of IL-17A.
  • Phenotypic analysis of skin lesions to assess dermatitis severity and characteristics.
  • Evaluation of comorbidities associated with the induced psoriasis-like condition.

Main Results:

  • Ectopic expression of IL-17A in keratinocytes led to spontaneous, severe psoriasis-like dermatitis in mice.
  • The developed mouse model exhibited characteristic features of human psoriasis.
  • The model also recapitulated typical comorbidities observed in human psoriasis patients.

Conclusions:

  • IL-17A is a potent inducer of psoriasis-like skin inflammation.
  • Mouse models with IL-17A overexpression are valuable tools for studying psoriasis pathogenesis and IL-17 functions in pathological contexts.
  • These findings reinforce IL-17 as a validated therapeutic target for psoriasis and other IL-17-mediated inflammatory diseases.